Detalles de la búsqueda
1.
Melanoma clonal heterogeneity leads to secondary resistance after adoptive cell therapy with tumor-infiltrating lymphocytes.
Cancer Immunol Res;
2024 Apr 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-38631025
2.
Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study.
Lancet Oncol;
13(12): 1234-41, 2012 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-23153506
3.
A multicenter phase II trial of anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple negative breast cancer.
Sci Rep;
13(1): 3705, 2023 03 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36879012
4.
Plinabulin, a Distinct Microtubule-Targeting Chemotherapy, Promotes M1-Like Macrophage Polarization and Anti-tumor Immunity.
Front Oncol;
11: 644608, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33747968
5.
First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13).
Eur J Cancer;
96: 6-16, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29660598
6.
PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy.
Clin Cancer Res;
24(1): 120-129, 2018 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29066507
7.
mTORC1/autophagy-regulated MerTK in mutant BRAFV600 melanoma with acquired resistance to BRAF inhibition.
Oncotarget;
8(41): 69204-69218, 2017 Sep 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-29050198
8.
EGFR-targeted immunoliposomes derived from the monoclonal antibody EMD72000 mediate specific and efficient drug delivery to a variety of colorectal cancer cells.
J Drug Target;
14(4): 215-23, 2006 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-16777680
9.
Simultaneous targeting of VEGF-receptors 2 and 3 with immunoliposomes enhances therapeutic efficacy.
J Drug Target;
24(1): 80-9, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-26204325
10.
Large-scale manufacturing of GMP-compliant anti-EGFR targeted nanocarriers: production of doxorubicin-loaded anti-EGFR-immunoliposomes for a first-in-man clinical trial.
Int J Pharm;
484(1-2): 8-15, 2015 Apr 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-25701632
11.
Immunoliposomal delivery of doxorubicin can overcome multidrug resistance mechanisms in EGFR-overexpressing tumor cells.
J Drug Target;
20(5): 422-32, 2012 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-22519893
12.
Targeting tumor-associated endothelial cells: anti-VEGFR2 immunoliposomes mediate tumor vessel disruption and inhibit tumor growth.
Clin Cancer Res;
18(2): 454-64, 2012 Jan 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-22065082
Resultados
1 -
12
de 12
1
Próxima >
>>